377 related articles for article (PubMed ID: 34817208)
1. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma.
Deere JD; Carroll TD; Dutra J; Fritts L; Sammak RL; Yee JL; Olstad KJ; Reader JR; Kistler A; Kamm J; Di Germanio C; Shaan Lakshmanappa Y; Elizaldi SR; Roh JW; Simmons G; Watanabe J; Pollard RE; Usachenko J; Immareddy R; Schmidt BA; O'Connor SL; DeRisi J; Busch MP; Iyer SS; Van Rompay KKA; Hartigan-O'Connor DJ; Miller CJ
Microbiol Spectr; 2021 Dec; 9(3):e0139721. PubMed ID: 34817208
[TBL] [Abstract][Full Text] [Related]
2. Convalescent plasma - Is it useful for treating SARS Co-V2 infection?
Ranganathan S; Iyer RN
Indian J Med Microbiol; 2020; 38(3 & 4):252-260. PubMed ID: 33154232
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
4. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response.
Herman JD; Wang C; Loos C; Yoon H; Rivera J; Eugenia Dieterle M; Haslwanter D; Jangra RK; Bortz RH; Bar KJ; Julg B; Chandran K; Lauffenburger D; Pirofski LA; Alter G
Nat Commun; 2021 Nov; 12(1):6853. PubMed ID: 34824251
[TBL] [Abstract][Full Text] [Related]
5. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation.
Van Rompay KKA; Olstad KJ; Sammak RL; Dutra J; Watanabe JK; Usachenko JL; Immareddy R; Roh JW; Verma A; Shaan Lakshmanappa Y; Schmidt BA; Di Germanio C; Rizvi N; Liu H; Ma ZM; Stone M; Simmons G; Dumont LJ; Allen AM; Lockwood S; Pollard RE; Ramiro de Assis R; Yee JL; Nham PB; Ardeshir A; Deere JD; Jain A; Felgner PL; Coffey LL; Iyer SS; Hartigan-O'Connor DJ; Busch MP; Reader JR
PLoS Pathog; 2022 Apr; 18(4):e1009925. PubMed ID: 35443018
[TBL] [Abstract][Full Text] [Related]
6. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Yu J; Tostanoski LH; Peter L; Mercado NB; McMahan K; Mahrokhian SH; Nkolola JP; Liu J; Li Z; Chandrashekar A; Martinez DR; Loos C; Atyeo C; Fischinger S; Burke JS; Slein MD; Chen Y; Zuiani A; Lelis FJN; Travers M; Habibi S; Pessaint L; Van Ry A; Blade K; Brown R; Cook A; Finneyfrock B; Dodson A; Teow E; Velasco J; Zahn R; Wegmann F; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kirilova M; Kordana N; Lin Z; Maxfield LF; Nampanya F; Nityanandam R; Ventura JD; Wan H; Cai Y; Chen B; Schmidt AG; Wesemann DR; Baric RS; Alter G; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):806-811. PubMed ID: 32434945
[TBL] [Abstract][Full Text] [Related]
7. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
8. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
9. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
[TBL] [Abstract][Full Text] [Related]
10. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.
Cross RW; Prasad AN; Borisevich V; Woolsey C; Agans KN; Deer DJ; Dobias NS; Geisbert JB; Fenton KA; Geisbert TW
Cell Rep; 2021 Mar; 34(10):108837. PubMed ID: 33662255
[TBL] [Abstract][Full Text] [Related]
11. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
Corbett KS; Flynn B; Foulds KE; Francica JR; Boyoglu-Barnum S; Werner AP; Flach B; O'Connell S; Bock KW; Minai M; Nagata BM; Andersen H; Martinez DR; Noe AT; Douek N; Donaldson MM; Nji NN; Alvarado GS; Edwards DK; Flebbe DR; Lamb E; Doria-Rose NA; Lin BC; Louder MK; O'Dell S; Schmidt SD; Phung E; Chang LA; Yap C; Todd JM; Pessaint L; Van Ry A; Browne S; Greenhouse J; Putman-Taylor T; Strasbaugh A; Campbell TA; Cook A; Dodson A; Steingrebe K; Shi W; Zhang Y; Abiona OM; Wang L; Pegu A; Yang ES; Leung K; Zhou T; Teng IT; Widge A; Gordon I; Novik L; Gillespie RA; Loomis RJ; Moliva JI; Stewart-Jones G; Himansu S; Kong WP; Nason MC; Morabito KM; Ruckwardt TJ; Ledgerwood JE; Gaudinski MR; Kwong PD; Mascola JR; Carfi A; Lewis MG; Baric RS; McDermott A; Moore IN; Sullivan NJ; Roederer M; Seder RA; Graham BS
N Engl J Med; 2020 Oct; 383(16):1544-1555. PubMed ID: 32722908
[TBL] [Abstract][Full Text] [Related]
14. Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Antibody Titers in Convalescent Plasma and Recipients in New Mexico: An Open Treatment Study in Patients With Coronavirus Disease 2019.
Bradfute SB; Hurwitz I; Yingling AV; Ye C; Cheng Q; Noonan TP; Raval JS; Sosa NR; Mertz GJ; Perkins DJ; Harkins MS
J Infect Dis; 2020 Oct; 222(10):1620-1628. PubMed ID: 32779705
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 infection protects against rechallenge in rhesus macaques.
Chandrashekar A; Liu J; Martinot AJ; McMahan K; Mercado NB; Peter L; Tostanoski LH; Yu J; Maliga Z; Nekorchuk M; Busman-Sahay K; Terry M; Wrijil LM; Ducat S; Martinez DR; Atyeo C; Fischinger S; Burke JS; Slein MD; Pessaint L; Van Ry A; Greenhouse J; Taylor T; Blade K; Cook A; Finneyfrock B; Brown R; Teow E; Velasco J; Zahn R; Wegmann F; Abbink P; Bondzie EA; Dagotto G; Gebre MS; He X; Jacob-Dolan C; Kordana N; Li Z; Lifton MA; Mahrokhian SH; Maxfield LF; Nityanandam R; Nkolola JP; Schmidt AG; Miller AD; Baric RS; Alter G; Sorger PK; Estes JD; Andersen H; Lewis MG; Barouch DH
Science; 2020 Aug; 369(6505):812-817. PubMed ID: 32434946
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin.
Volk A; Covini-Souris C; Kuehnel D; De Mey C; Römisch J; Schmidt T
BioDrugs; 2022 Jan; 36(1):41-53. PubMed ID: 34843105
[TBL] [Abstract][Full Text] [Related]
17. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
[TBL] [Abstract][Full Text] [Related]
18. Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
Takamatsu Y; Imai M; Maeda K; Nakajima N; Higashi-Kuwata N; Iwatsuki-Horimoto K; Ito M; Kiso M; Maemura T; Takeda Y; Omata K; Suzuki T; Kawaoka Y; Mitsuya H
J Virol; 2022 Feb; 96(4):e0155121. PubMed ID: 34818068
[TBL] [Abstract][Full Text] [Related]
19. Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques.
Beddingfield BJ; Maness NJ; Spencer S; Rappaport J; Aye PP; Russell-Lodrigue K; Doyle-Meyers LA; Blair RV; Gao H; Montefiori D; Roy CJ
Front Immunol; 2023; 14():1085883. PubMed ID: 36845143
[TBL] [Abstract][Full Text] [Related]
20. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
